Cyclerion Therapeutics Inc (OQ:CYCN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 301 Binney St
CAMBRIDGE MA 02142-1030
Tel: N/A
Website: N/A
IR: N/A
<
Key People
N/A    
Business Overview
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company's portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
Financial Overview
For the nine months ended 30 September 2019, Cyclerion Therapeutics Inc revenues increased from $0K to $3M. Net loss increased 15% to $97M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development - Balancing value increase of 13% to $67.7M (expense), Stock-based Compensation in SGA increase from $3.5M to $8.4M (expense).
Employees: 140 as of Feb 28, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $9.60M as of Sep 30, 2019
Annual revenue (TTM): $3.03M as of Sep 30, 2019
EBITDA (TTM): -$126.84M as of Sep 30, 2019
Net annual income (TTM): -$127.85M as of Sep 30, 2019
Free cash flow (TTM): -$111.73M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 27,468,445 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization